Image Response Assessment Team (IRAT) Shared Resource PROJECT SUMMARY Radiology began as a discipline that specialized in the visualization of anatomy. In the context of cancer, modern technologies and innovations transformed imaging into a non-invasive tool that not only assesses solid tumor size and shape but also interrogates the spatial heterogeneity within tumors on the basis of their radiologic appearance, metabolism, and physiology. The overall goal of the Image Response Assessment Team (IRAT) Shared Resource is to enhance the scientific quality of clinical studies, by offering a single point of entry for Moffitt Cancer Center (MCC) members to access traditional and advanced quantitative image analysis services. To this end, efforts are organized around three Specific Aims, which are to: 1) maintain and improve the high reliability and fast turnaround times for RECIST (Response Evaluation Criteria in Solid Tumors) and other standard tumor assessment metrics; 2) improve therapeutic trials at MCC by translating research advances in radiomics and multi-parameter MRI (mpMRI) analyses into turnkey imaging biomarker services; and 3) provide members with access to non-traditional imaging endpoints for therapeutic trials. IRAT consists of five full-time staff and provides quantitative image-based tumor metrics to support investigator- initiated, cooperative group, and industry-sponsored clinical trials at MCC, and is part of the national consortium of Cancer Center IRATs. IRAT has essential roles in the MCC mission ?to contribute to the prevention and cure of cancer,? by providing the support and services necessary to integrate both traditional and innovative imaging endpoints into clinical trials and by providing quality assurance and control throughout the process to yield scientifically valid results. With rapid advances in treatment paradigms such as immunotherapies, IRAT provides improved imaging endpoints to meet the needs of these cutting-edge studies of MCC members. IRAT has witnessed sustained increases in the volume of quantitative image response assessment services provided. A total of 298 new trials requiring imaging response assessment were activated in FY11-15, rising from 39 in FY11 to 65 in FY15. Developing an infrastructure for IRAT has permitted the pursuit of other funded trial opportunities that use advanced and/or investigational imaging techniques, analyses, and novel biomarkers. For example, IRAT is supporting multiple grant applications and funded projects by members investigating radiomic and mpMRI imaging biomarkers in retrospective and prospective clinical and pre-clinical studies. During the past project period, IRAT served 34 members from 4 MCC Programs. Overall usage by members was 94%, with 63% of total usage supporting members with peer- reviewed funding. IRAT-supported studies resulted in a total of 62 peer-reviewed scientific publications during this period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA076292-19
Application #
9209818
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Project Start
Project End
Budget Start
2017-02-01
Budget End
2018-01-31
Support Year
19
Fiscal Year
2017
Total Cost
$88,276
Indirect Cost
$36,953
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
Research Institutes
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
de Mingo Pulido, Álvaro; Gardner, Alycia; Hiebler, Shandi et al. (2018) TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. Cancer Cell 33:60-74.e6
Divakaran, Anand; Talluri, Siva K; Ayoub, Alex M et al. (2018) Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor. J Med Chem 61:9316-9334
McIntyre, Jessica; Jiménez, Julio; Rivera, Yonaira M et al. (2018) Comparison of Health Communication Channels for Reaching Hispanics About Biobanking: a Pilot Trial. J Cancer Educ 33:833-841
Li, Gongbo; Boucher, Justin C; Kotani, Hiroshi et al. (2018) 4-1BB enhancement of CAR T function requires NF-?B and TRAFs. JCI Insight 3:
Rivera, Y M; Moreno, L; Briant, K J et al. (2018) Developing Sustainable Cancer Education Programs: Training Public Health Students to Deliver Cancer 101 in Puerto Rico. J Cancer Educ 33:128-133
Saltos, Andreas; Khalil, Farah; Smith, Michelle et al. (2018) Clinical associations of mucin 1 in human lung cancer and precancerous lesions. Oncotarget 9:35666-35675
Gjyshi, Anxhela; Dash, Sweta; Cen, Ling et al. (2018) Early transcriptional response of human ovarian and fallopian tube surface epithelial cells to norepinephrine. Sci Rep 8:8291
Maharaj, Kamira; Powers, John J; Achille, Alex et al. (2018) Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia. Blood Adv 2:3012-3024
Schaal, Courtney M; Bora-Singhal, Namrata; Kumar, Durairaj Mohan et al. (2018) Regulation of Sox2 and stemness by nicotine and electronic-cigarettes in non-small cell lung cancer. Mol Cancer 17:149
Zhu, Genyuan; Brayer, Jason; Padron, Eric et al. (2018) OMIP-049: Analysis of Human Myelopoiesis and Myeloid Neoplasms. Cytometry A 93:982-986

Showing the most recent 10 out of 1254 publications